1.
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
;
(12): 953-959, 2020.
Article
in Chinese
| WPRIM
| ID: wpr-824998
ABSTRACT
@#Programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) signaling pathway has been found capable of affecting anti-tumor immune effect in many malignancies in recent years. Patients who are diagnosed with advanced non-small cell lung cancer (NSCLC) have considerable responses after receving inhibitors against PD-1/PD-L1. This paper reviews the clinical progress of PD-1/PD-L1 inhibitors in the treatment of NSCLC.